You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Biosimilars in the Real World: Perspectives for Staying Within the Scope of Care

  • Authors: Jonathan Kay, MD; Sameer V. Awsare, MD, FACP; Bhavesh Shah, RPh, BCOP
  • CME / ABIM MOC / CE Released: 11/10/2022; Reviewed and Renewed: 11/10/2023
  • Valid for credit through: 11/10/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE: 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians (PCPs), rheumatologists, gastroenterologists, dermatologists, endocrinologists, and hematologists/oncologists, nurses/nurse practitioners, and pharmacists.

The goal of this activity is for the learner to better be able to understand the process and implications of using or substituting a biosimilar or interchangeable product as part of the interprofessional team.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Characteristics of substitution and interchangeability
  • Have greater competence/performance related to
    • Substituting a biosimilar as part of the clinical management of a patient
  • Demonstrate greater confidence in their ability to
    • Coordinate with the interprofessional team to optimize the care of patients receiving biosimilars


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Jonathan Kay, MD

    Timothy S. and Elaine L. Peterson Chair in Rheumatology
    Medicine and Population and Quantitative Health Sciences
    UMass Chan Medical School
    UMass Memorial Medical Center
    Worcester, Massachusetts


    Jonathan Kay, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Alvotech Suisse AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Celltrion Healthcare; Granite Bio AG; Jubilant Radiopharma; Pfizer, Inc.; Related Sciences; Samsung Bioepis; Scipher Medicine; UCB Pharma, Inc.
    Research funding from: Aker BioMarine; AMPEL BioSolutions; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corp.; Pfizer, Inc.; UCB Pharma, Inc.
    Owns stock (privately owned) in: Related Sciences

  • Sameer V. Awsare, MD, FACP

    Associate Executive Director
    Permanente Medical Group
    Oakland, California


    Sameer V. Awsare, MD, FACP, has no relevant financial relationships.

  • Bhavesh Shah, RPh, BCOP

    Chief Pharmacy Officer
    Boston Medical Center
    Boston, Massachusetts


    Bhavesh Shah, RPh, BCOP, has no relevant financial relationships.


  • Christina T. Loguidice, BA

    Medical Education Director, Medscape, LLC


    Christina T. Loguidice, BA, has disclosed no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-343-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Biosimilars in the Real World: Perspectives for Staying Within the Scope of Care


Educational Impact Challenge

The goal of this activity is for the learner to better be able to understand the process and implications of using or substituting a biosimilar or interchangeable product as part of the interprofessional team.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print